10-Q: Dyadic International Reports First Quarter 2025 Financial Results

Dyadic International, Inc. released its first quarter 2025 financial results, marked by decreased revenue and a net loss, but with sufficient cash reserves for the next twelve months.

Summary

• Dyadic International, a biotechnology platform company, reported a net loss of $2,027,579 for the first quarter of 2025, compared to a net loss of $2,009,596 in the same period of 2024.
• Research and development revenue decreased to $183,100 from $334,617 in Q1 2024, primarily due to fewer collaborations.
• The company received grant revenue of $210,472 in Q1 2025, related to the Gates Foundation and CEPI grants, compared to no grant revenue in Q1 2024.
• General and administrative expenses decreased by 10.8% to $1,596,338 compared to $1,788,594 in Q1 2024.
• Dyadic expects its current cash, cash equivalents, and investment securities of $7,349,413 to be sufficient for the next twelve months.
• The company raised $6 million in convertible notes in March 2024 and received grants from the Gates Foundation ($3,092,136) and CEPI ($2.4 million).
• Dyadic is focused on developing its C1 and Dapibus protein production platforms for pharmaceutical and non-pharmaceutical applications.
• The company anticipates commercializing certain functional recombinant products in 2025.

Sentiment

Score: 6

Explanation: While the company reported a net loss and decreased revenue, the significant grant funding, sufficient cash reserves, and progress towards commercialization provide a balanced outlook. The company’s future success hinges on its ability to execute its commercialization strategy and achieve profitability.

Positives

• Dyadic secured significant grant funding from the Gates Foundation and CEPI, totaling $5.49 million, to advance its C1 platform for vaccine and antibody development.
• The company has sufficient cash reserves to cover operational expenses for the next twelve months.
• General and administrative expenses decreased, indicating improved cost management.
• Dyadic is making progress towards commercializing several functional recombinant products in 2025, including human serum albumin, transferrin, growth factors, and dairy enzymes.
• The company successfully completed a Phase 1 first-in-human study for a vaccine antigen produced using C1, demonstrating its safety for human applications.
• Dyadic expanded its partnership with Phibro Animal Health/Abic for livestock applications.

Negatives

• Dyadic reported a net loss for Q1 2025, although slightly improved compared to Q1 2024.
• Research and development revenue decreased significantly compared to the same period in 2024 due to fewer collaborations.

Risks

• Dyadic’s history of net losses raises concerns about its long-term profitability.
• The company faces competition from alternative technologies in the biotechnology market.
• The success of Dyadic depends on its ability to secure regulatory approvals for its products and achieve commercialization.
• The company relies on third-party collaborations and contract research organizations, which can pose risks to project timelines and outcomes.
• Dyadic is subject to intellectual property risks, and the protection of its proprietary technology is crucial for its success.
• Changes in global economic and financial conditions could impact the company’s operations and financing.
• The company may need to raise additional capital in the future, which could dilute existing shareholders.
• Dyadic is exposed to foreign currency exchange rate fluctuations due to its international operations.

Future Outlook

Dyadic expects its existing cash, cash equivalents, and investment securities to be sufficient for operational needs for the next twelve months. The company anticipates commercializing certain functional recombinant products in 2025 and continues to develop its C1 and Dapibus platforms for pharmaceutical and non-pharmaceutical applications. However, the company acknowledges that these estimates are based on assumptions that may prove inaccurate, and its operating plan could change due to unforeseen factors. Dyadic may seek additional capital through various means if needed, which could be dilutive to existing shareholders.

Industry Context

Dyadic’s focus on developing microbial protein production platforms aligns with the growing demand for biopharmaceuticals and alternative protein sources. The company’s expansion into functional recombinant solutions for non-pharmaceutical applications positions it to capitalize on the increasing demand in research, nutrition, and industrial markets. The biotechnology industry is highly competitive, with ongoing advancements in alternative technologies. Dyadic’s success will depend on its ability to differentiate its platforms and secure partnerships to drive commercialization.

Legal Proceedings

• Dyadic is not currently involved in any material litigation.

Related Party Transactions

• $2 million of the $6 million convertible notes issued in March 2024 were sold to related parties, including family members and trusts of the CEO.

Stakeholder Impact

• The company’s financial performance and progress towards commercialization impact shareholders.
• Employees are affected by the company’s research and development activities and overall success.
• Customers and partners in research, nutrition, and industrial markets will be impacted by the availability and commercialization of Dyadic’s products.
• Potential future capital raising could dilute existing shareholders.

Next Steps

• Dyadic plans to commercialize several functional recombinant products in 2025.
• The company will continue developing its C1 and Dapibus platforms for various applications.
• Dyadic will participate in the inaugural European Vaccines Hub for Pandemic Readiness meeting in May 2025.
• The company may seek additional capital if needed.

Key Dates

Keywords

Biotechnology, Protein Production Platforms, C1 Platform, Dapibus Platform, Pharmaceuticals, Vaccines, Antibodies, Enzymes, Recombinant Proteins, Cell Culture Media, Animal Health, Gates Foundation, CEPI, Financial Results